Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04629547
PHASE2
Sleep Trial to Prevent Alzheimer's Disease
Sponsor: Washington University School of Medicine
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2022-05-25
Completion Date
2026-05
Last Updated
2025-12-17
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Suvorexant 20 mg
Suvorexant 20mg will be taken nightly for 24 months.
DRUG
Placebo
Placebo will be taken nightly for 24 months.
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States